The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AmbotzGBB1134     9-phenyl-5,8,10- trioxabicyclo[4.4.0]decane...

Synonyms: AGN-PC-00055C, AG-E-98338, B7416_SIGMA, SureCN12032224, NSC-243486, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Benzylidene glucose


High impact information on Benzylidene glucose


Biological context of Benzylidene glucose

  • Testing loss of colony forming ability following a 24 h exposure, the IC50 values, i.e. inhibitory doses that reduced the number of surviving treated cells by one half, were found to range from 3.2 to 10.8 mM BG and from 1.3 to 7.7 mM P-1013 [5].
  • Effect on cell survival and protein synthesis of benzylidene-glucose (BG) and the deuterated analogue P-1013 in cultured cells [5].

Anatomical context of Benzylidene glucose


Analytical, diagnostic and therapeutic context of Benzylidene glucose

  • Histological examinations of each tumor showed that P-1013 treatment of pancreatic xenografts reduced tumor volume without inducing greater necrosis than that comparable to respective control tumors [2].
  • For the ovarian xenograft, the histological examination indicated a higher fraction of tumors with more than 50% necrotic tissue in two of the P-1013-treated groups compared with the control group (Fisher exact test, p = 0.12) [2].


  1. In vivo and in vitro pharmacokinetics of 4,6-benzylidene-D-glucose (BG) in rats. Dornish, J.M., Larsen, R.O., Schwarze, P.E., Børretzen, B., Pettersen, E.O. Investigational new drugs. (1990) [Pubmed]
  2. Growth inhibition of human tumor xenografts in nude mice by treatment with the antitumor agent 4,6-benzylidene-d1-D-glucose (P-1013). Dunsaed, C.B., Dornish, J.M., Aastveit, T.E., Nesland, J.M., Pettersen, E.O. Anticancer Drugs (1995) [Pubmed]
  3. Antitumour effect of benzylidene-glucose (BG) in rats with chemically induced hepatocellular carcinoma. Pettersen, E.O., Schwarze, P.E., Dornish, J.M., Nesland, J.M. Anticancer Res. (1986) [Pubmed]
  4. The bioavailability and dose dependency of the deuterated anti-tumour agent 4,6-benzylidene-d1-D-glucose in mice and rats. Dunsaed, C.B., Dornish, J.M., Pettersen, E.O. Cancer Chemother. Pharmacol. (1995) [Pubmed]
  5. Effect on cell survival and protein synthesis of benzylidene-glucose (BG) and the deuterated analogue P-1013 in cultured cells. Dunsaed, C.B., Dornish, J.M., Oftebro, R., Pettersen, E.O. Anticancer Res. (1995) [Pubmed]
WikiGenes - Universities